NCT01487395View on ClinicalTrials.gov

Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2013

Conditions
Alzheimer DiseaseBattery
Interventions
DRUG

Donepezil .

Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.

DRUG

Placebo

the placebo will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.

Trial Locations (3)

59037

CHRU de Lille/ Centre d'investigation Clinique, Lille

Unknown

CIC Marseille, Marseille

CIC Toulouse, Toulouse

All Listed Sponsors
collaborator

Innovative Medicines Initiative

OTHER

lead

University Hospital, Lille

OTHER

NCT01487395 - Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development | Biotech Hunter | Biotech Hunter